Never miss a story

Get subscribed to our newsletter


×
The researchers are calling for prioritizing clinical trials of drugs targeting the proteins IFNAR2 and ACE2. Pixabay

A new study using human genetics suggests that researchers should prioritize clinical trials of drugs that target two proteins to manage Covid-19 in its early stages. Based on their analyses, the researchers are calling for prioritizing clinical trials of drugs targeting the proteins IFNAR2 and ACE2.

The goal is to identify existing drugs that can be re-purposed for the early management of Covid-19, said the team from Veterans Affairs Boston Healthcare System in the US in a paper in the journal Nature Medicine.IFNAR2 is the target for approved drugs often used by patients with relapsing forms of the central nervous system disorder multiple sclerosis.


Follow NewsGram on LinkedIn to know what’s happening around the world.

The researchers believe the most promising ACE2 therapy against Covid-19 is a drug that was developed before the pandemic began and has been evaluated in clinical trials to reduce the inflammatory response in patients with severe respiratory disorders.

“When we started this project early last summer, most COVID-19 trials were being done on hospitalized patients,” said Dr. Juan P Casas, a physician epidemiologist at the Veterans Affairs Boston Healthcare System.” The problem we tried to overcome is how to identify if existing drugs, either approved or in clinical development for other conditions, can be repurposed for the early management of Covid-19,” he added.


The drug works by confusing the coronavirus so it attaches to the drug instead of the ACE2 protein in the human cell. Pixabay

ACE2 is highly relevant to Covid-19 because the coronavirus uses that protein to enter human cells. The most promising ACE2 therapy against COVID-19 is the drug APN01, which mimics the protein. The drug works by confusing the coronavirus so it attaches to the drug instead of the ACE2 protein in the human cell.

Positive evidence is emerging from small clinical trials on the effectiveness of APN01 in COVID-19 patients, especially those that are hospitalized.”Hence, if our genetic findings are correct, there’s a need to test this strategy in clinical trials in COVID-19 outpatients,” Casas noted.

ALSO READ: Jumping Genes Likely To Protect Against Certain Blood Cancers

The researchers also showed that people with a certain variant of IFNAR2 had less chance of being hospitalized due to COVID-19, compared to people without the variant. Casas said he sees a continued need for drugs to treat people in the early phase of COVID-19, despite the ongoing worldwide vaccination campaigns.

“This is largely due to two reasons,” he says. “First, it will take some time to achieve the high levels of vaccine coverage needed to create herd immunity. In addition, certain coronavirus variants are emerging that seem to lead to reduced vaccine efficiency. We are not yet in the clear.” (IANS/JC)


Popular

Kishu Inu and Dogelon Mars are some of the more popular canine coins in recent months. Their popularity is demonstrated by the vast amount of trading volume that these cryptocurrencies receive.

At the time of writing, Kishu Inu has a trading volume exceeding $10 million and Dogelon Mars has an even larger trading volume that surpasses $30 million.

Keep Reading Show less

HUH Token

It’s here, and it appears that there ain’t nothin’ or no one stopping the skyrocketing force of HUH Token and the release of the long-awaited White Paper is finally here and we’re living for it.

It’s also great to note that Shiba Inu made a triumphant crypto market return this week and the reign of the dog continues though with HUH Token’s White Paper release it could see the ‘Utimeme’ token break out of the atmosphere on its December 6th launch and surpass Shiba Inu for altcoin supremacy.

Keep Reading Show less

HUH Token

HUH Token has been on the lips of crypto lovers for some time now and the much-anticipated White Paper release is here, right now, today!

Not only this but Shiba Inu’s mastery of the altcoin world could be coming to an end on HUH Token’s December 6th release if the aims, goals and technology in the White Paper are anything to go by.

Keep reading... Show less